Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients

Introduction: The efficacy and tolerability of Enzalutamide and Abiraterone Acetate have been reported in elderly patients with metastatic castration resistant prostate cancer (mCRPC). However, there is no randomized study directly comparing antitumor effects between these 2 agents in geriatric...

Повний опис

Бібліографічні деталі

Автори:	Ali Alkan, Zeynep Gülsüm Güç, Mustafa Gürbüz, Güliz Özgün, Serkan Değirmencioğlu, Mutlu Doğan, Tuğba Akın Telli, Özge Keskin, Çağatay Arslan, Burak Bilgin, Sema Sezgin Göksu, Hacer Demir, Elif Berna Köksoy, Osman Köstek, İsmail Ertürk, Teoman Şakalar, Arzu Yaşar, Görkem Türkkan, Büşra Kasım, Aziz Karaoğlu, Berna Çakmak Öksüzoğlu, Fulden Yumuk, Mehmet Ali Şendur, Hasan Şenol Coşkun, İrfan Çiçin, Nuri Karadurmuş, Özgür Tanrıverdi, Hakan Akbulut, Yüksel Ürün
Формат:	Artigo
Мова:	Inglês
Опубліковано:	MRE Press 2021-09-01
Серія:	Journal of Men's Health
Предмети:	metastatic castration-resistant prostate cancer enzalutamide abiraterone acetate elderly
Онлайн доступ:	https://oss.jomh.org/jomh/article/20210928-455/pdf/JOMH2021011801.pdf
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!